NCT06866106 Well-being in IBS: Strengths and Happiness (WISH) 2.0
| NCT ID | NCT06866106 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Irritable Bowel Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-10-30 |
| Primary Completion | 2028-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-10-30 with a primary completion date of 2028-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to examine the feasibility, acceptability, preliminary effects, and candidate gut-brain mechanisms of an optimized positive psychology (PP) intervention for patients with irritable bowel syndrome (IBS), entitled "WISH," compared to an educational control intervention.
Eligibility Criteria
Inclusion Criteria: * IBS Diagnosis: Adult patients with an IBS diagnosis meeting standardized Rome IV diagnostic criteria. * Language and communication: English fluency and access to a phone. Exclusion Criteria: * Presence of inflammatory bowel disease or other structural/biochemical primary gastrointestinal illness that better explains IBS-like symptoms: As reported by the patient, their physician, and/or documented in the medical record. * Severe psychiatric illness: Current manic episode, psychosis, or active substance use disorder diagnosed via the Mini International Neuropsychiatric Interview (MINI) or Diagnostic Interview for Anxiety, Mood, and OCD and Related Neuropsychiatric Disorders (DIAMOND). * Cognitive impairment: Assessed using a six-item cognitive screen developed for research. * Presence of atrial fibrillation or a cardiac pacemaker, or daily use of beta blocking medication: As reported by the patient and/or documented in the medical record. * Plans to start or participate in another new behavioral health intervention or psychotherapy during the study period.
Contact & Investigator
Elizabeth N Madva, MD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT06866106 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Irritable Bowel Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06866106 currently recruiting?
Yes, NCT06866106 is actively recruiting participants. Contact the research team at emadva@mgh.harvard.edu for enrollment information.
Where is the NCT06866106 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06866106 clinical trial?
NCT06866106 is sponsored by Massachusetts General Hospital. The principal investigator is Elizabeth N Madva, MD at Massachusetts General Hospital. The trial plans to enroll 50 participants.